MedPath

The effect of an anti-VEGF drug on proliferative retinopathy.

Not Applicable
Conditions
Diabetic retinopathy
Registration Number
JPRN-jRCTs031180307
Lead Sponsor
Kitano Shigehiko
Brief Summary

Intravitreal injection of aflibercept did not change the area of the non-perfusion area of the retina.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
2
Inclusion Criteria

Diabetic retinopathy with macular edema and non-perfusion area

Exclusion Criteria

Posttreatment for diabetic retinopath

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change of non-perfusion area
Secondary Outcome Measures
NameTimeMethod
Change of visual acuity, retinal thickness and neovascularization
© Copyright 2025. All Rights Reserved by MedPath